EMA fol­lows FDA to ap­prove Roche's Tecen­triq com­bo for front­line use in triple neg­a­tive breast can­cer

Months af­ter Roche se­cured US ap­proval for its check­point in­hibitor Tecen­triq, in com­bi­na­tion with Cel­gene’s Abrax­ane, for front­line use in an ag­gres­sive, tough-to-treat sub­group …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER